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Isoflurane does not cause neuroapoptosis but
reduces astroglial processes in young adult mice
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Abstract
Background: Isoflurane, a volatile anesthetic widely used clinically, has been implicated to be both
neuroprotective and neurotoxic. The claim about isoflurane causing neural apoptosis remains controversial. In this
study, we investigated the effects of isoflurane exposures on apoptotic and anti-apoptotic signals, cell proliferation
and neurogenesis, and astroglial processes in young adult mouse brains.
Methods: Sixty 6-week-old mice were randomly assigned to four anesthetic concentration groups (0 as control
and 0.6%, 1.3%, and 2%) with four recovery times (2 h and 1, 6, and 14 d) after 2-h isoflurane exposure.
Immunohistochemistry measurements of activated caspase-3 and Bcl-xl for apoptotic and anti-apoptotic signals,
respectively, glial fibrillary acidic protein (GFAP) and vimentin for reactive astrocytosis, doublecortin (Dcx) for
neurogenesis, and BrdU for cell proliferation were performed.
Results: Contrary to the previous conclusion derived from studies with neonatal rodents, we found no evidence of
isoflurane-induced apoptosis in the adult mouse brain. Neurogenesis in the subgranule zone of the dentate gyrus
was not affected by isoflurane. However, there is a tendency of reduced cell proliferation after 2% isoflurane
exposure. VIM and GFAP staining showed that isoflurane exposure caused a delayed reduction of astroglial
processes in the hippocampus and dentate gyrus.
Conclusion: Two-hour exposure to isoflurane did not cause neuroapoptosis in adult brains. The delayed reduction
in astroglial processes after isoflurane exposure may explain why some volatile anesthetics can confer
neuroprotection after experimental stroke because reduced glial scarring facilitates better long-term neuronal
recoveries.
Introduction
Volatile anesthetics have been implicated to be both
neuroprotective and neurotoxic. Several studies have
shown that volatile anesthetics can reduce neurological
damage from ischemia by reducing glutamate release,
blocking glutamate receptors, enhancing hyperpolariza-
tion by GABA, increasing anti-apoptotic bcl-2 levels,
activating p38 mitogen-activated protein kinases, and
inducing neurogenesis [1-3]. Conversely, isoflurane has
also been implicated in post-anesthesia cognitive
decline, possible interaction and exacerbation of the
accumulation of amyloid-b plaques found in Alzheimer’s
disease, and apoptosis in the developing brain [4,5].
It has been proposed that a prolonged exposure to
volatile anesthetics is intrinsically neurotoxic and the
observed protective effects are due to preconditioning,
in which endogenous neuroprotective mechanisms are
initiated by a limited exposure [6]. Further investigations
in cell cultures suggest that isoflurane preconditioning
can protect astrocytes [7]. However, other studies have
showed that isoflurane impairs immature astroglia devel-
opment [8]. The anesthetic effects on astrocytes remain
controversial.
To investigate the mechanisms of isoflurane-induced
neurological changes, degrees of neurogenesis, apoptosis,
and reactive astrocytosis were studied in adult mice after
exposure to various concentrations of isoflurane and
recovery for different lengths of time after exposure.
Similar to the results in a recent study [3], we found no
evidence of brain cell death or neurogenesis in young
adult mice after isoflurane anesthesia. However, our
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study additionally investigated the effect of isoflurane on
astroglial processes. A decrease in glial fibrillary acidic
protein (GFAP) and vimentin (VIM) in the hippocampal
molecular layer (stratum lacunosum moleculare, SLM),
dentate gyrus granular layer (DG), and dentate gyrus
hilus was seen at later time points in isoflurane-anesthe-
tized mice.
Materials and methods
Animal Groups
Animal protocol was approved by the Institutional Ani-
mal Care and Use Committee at the University of Pitts-
burgh. Sixty 6-week-old male CD-1 mice weighing 35 ±
5 g were used for the experiments. We chose to use six-
week-old mice because synaptogenesis has completed in
these animals [9]. The use of young adult mice also
avoids the potential complications in older animals due
to the recently reported anesthetic-induced changes in
the neurodegenerative disorder-associated proteins
[10,11]. All animals were obtained from Harlan Labora-
tories (Frederick, MD) and randomly assigned to differ-
ent groups. Twelve mice did not expose to isoflurane
and were used as controls. Forty-eight mice were
assigned to three groups with continuous exposure to
isoflurane at concentrations of 0.6% (n = 12), 1.3% (n =
24), or 2% (n = 12) for two hours. In order to study the
anesthetic effects on cell proliferation, most animals
received two intraperitoneal bromodeoxyuridine (BrdU)
injections: 100 mg/kg 2 h before the exposure and 100
mg/kg after the exposure. We doubled the number of
animals in the group with 1.3% isoflurane, which is
close to the minimum alveolar concentration of isoflur-
ane in humans [12], so that half of these animals (n =
12) did not receive BrdU injection to rule out any
unforeseen effects from BrdU itself. The animals in the
control group were handled in the same way as those in
the three experimental groups except for isoflurane
exposure and were randomly assigned to “recover” for 2
h (n = 4), 1 d (n = 3), 6 d (n = 2), or 14 d (n = 3) after
handling. The animals in the experimental groups were
also equally subdivided into the same four recovery
times: 2 h and 1, 6, and 14 d after isoflurane exposure
(thus, n = 3 for each subgroup in the 0.6% and 2% iso-
flurane groups and in the 1.3% isoflurane groups with
and without BrdU injections). One mouse from each
recovery time point in the control group was also ran-
domly selected not to receive BrdU injections.
Isoflurane Anesthesia
All mice (including the controls) were placed in a stan-
dard 9.6-liter mouse cage with a steady flow of O2 as
the carrier gas and the desired percentage of isoflurane
at a flow rate of ~2 L/min through a plastic tubing for 2
h. A calibrated Datex Capnomac Ultima Gas Analyzer
(Datex Ohmeda, Helsinki, Finland) was used to ensure
that the isoflurane concentration inside the cage was
maintained at 0 (control), 0.6%, 1.3%, or 2%. During
anesthesia, a pulse oximeter (Starr Life Sciences, Oak-
mont, PA) was clipped onto the hindlegs of the animals
to monitor the oxygen saturation, heart rate, and
respiratory rate. A temperature probe was placed under
the ventral surfaces of the animals to ensure that the
body temperatures were maintained at 35-37 °C. After
anesthesia, mice were returned to their own cages and
given 2 h, 1, 6, or 14 d to recover. To avoid any poten-
tial complications from invasive manipulations, the
blood gases and end tidal CO2 of individual animals
were not measured. However, oxygen saturation in the
extremity (hindlegs) was maintained above 95%. A pre-
vious study in mice using the same anesthesia protocol
and the same O2 flow rate showed that ventilation
depression was insignificant with the isoflurane concen-
trations used in the present study [13].
Tissue Preparation
After the recovery periods, mice were anesthetized with
isoflurane and a transcardial perfusion was performed
with buffered 10% formalin phosphate, as described pre-
viously [14-16]. The brains were extracted from the
skulls and stored in buffered 10% formalin for 48 hours.
The tissue was then frozen-sectioned into 30 mm slices
using a Leica SM2000R (Leica, Germany) or a Lipshaw
50AB microtome. Sections from the hippocampal region
were randomly selected for immunostaining as detailed
below.
Immunostaining
Standard immunohistochemistry techniques were used
for GFAP, VIM, activated caspase-3, Bcl-xl, doublecortin
(Dcx), and BrdU staining. Mouse IgG1 anti-GFAP
(1:250) and Rabbit anti-Vimentin (1:200) were incubated
at room temperature for 2 hours. Secondary antibodies
used include: Alexa Fluor 594 donkey anti-rabbit (1:500)
and Alexa Fluor 488 goat anti-mouse IgG1 (1:500). Rab-
bit anti-activated caspase-3 (1:200) and mouse anti-Bcl-
xl (1:500) were incubated at 4°C overnight. Secondary
antibodies used were Alexa Fluor 488 goat anti-rabbit
(1:500) and Alexa Fluor 594 goat anti mouse IgG2a.
Goat anti-Dcx (1:250) was incubated at 4°C overnight.
The secondary antibody was Alexa Fluor 488 donkey
anti-goat (1:500). BrdU staining was performed by first
performing antigen retrieval by boiling tissue slices in
sodium citrate buffer. Rat anti-BrdU antibody (1:200)
was used as the primary antibody, and Alexa Fluor 488
donkey anti-rat (1:500) was used as the secondary anti-
body. Nuclear DNA was stained with 4’-6-diamino-2-
phenylindole (DAPI), 1 mg/ml, in phosphate-buffered
saline.
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Images were acquired using Image-Pro Plus 7.0 soft-
ware controlling an Olympus IX81 microscope (Olym-
pus America, Center Valley, PA) with a Prior motorized
stage, a Sutter Lambda xenon exciter light source, and
an ORCA-ER digital camera. All images were tiled using
Adobe Photoshop and post-processed using Image-Pro
AMS (Media Cypermetics, Inc., Bethesda, MD). Double-
cortin positive cell densities in the dentate gyrus subgra-
nular zone were determined by counting all Dcx+ cell
soma and then normalized by the area within which the
counting was performed. The percent positive areas for
GFAP+ and VIM+ cells in the dentate gyrus granular
layer, hilus, and the hippocampal SLM layer were deter-
mined by the well-established thresholding segmentation
method implemented in the Image-Pro processing pack-
age. To minimize thresholding bias, all tissue sections
were processed, stained, and imaged at the same time
using the same batch of staining media and the same
imaging acquisition setting. Two experimentalists with-
out knowledge of the resulting positive percentage areas
first determined the cut-off background values, which
were then averaged for each given staining and used in
the final thresholding segmentation measurements of
that staining. In few cases when the background inten-
sity of a given image was more than 1.5 standard devia-
tions outside the averaged background intensity, the
image’s own background threshold was used.
Statistics
Statistical analysis was performed using the SPSS pro-
gram (IBM Co., Armonk, NY). Multivariate analyses of
immunohistochemical staining were performed with
respect to BrdU injection, anesthetic concentration, and
days of recovery. A simple contrast test was performed
between animals with and without BrdU injection, and
between the control group and various groups with dif-
ferent isoflurane concentrations. Post hoc tests were car-
ried out for between-group comparison using either
Tukey’s honestly significant difference (HSD) test, Fish-
er’s least significant difference (LSD) test, or Dunnett t
test (2-sided against the control). The results are
reported as mean ± standard errors except otherwise
noted. For cell counts and area-averaged cell density,
comparison among different isoflurane concentration
groups, including the controls, was made using the non-
parametric Kruskal-Wallis test. A p value of <0.05 was
considered significant for all tests.
Results
One of the 12 mice in the 2% isoflurane group, which
was pre-assigned to 6-day recovery, died unexpectedly
due to unknown causes and was excluded from the ana-
lysis. To determine if 2-h exposure to clinically relevant
concentrations of isoflurane can induce apoptosis in
young adult mouse brains, we measured activated cas-
pase-3 as well as the anti-apoptosis regulator Bcl-xL
using immunohistochemical staining. The controls for
positive staining were obtained from brain tissues of
adult mice that underwent 20 min of hypoxia with 5%
oxygen, which is known to cause hypoxic tissue damage.
No measureable apoptotic or anti-apoptotic response
was detected in the isoflurane-exposed mice, as evi-
denced by the absence of any positive immunoreactivity
in the staining of activated caspase-3 and Bcl-xL (Figure
1). Therefore, unlike the situation in neonatal brains
where apoptosis is a natural process of eliminating neu-
rons that fail to establish synaptic connections, pro-
longed isoflurane exposure does not lead to apoptosis in
young adult brains.
In animals that received BrdU injections before and
after isoflurane exposure, we determined the isoflurane
effect on cell proliferation. Figure 2 depicts BrdU+ cell
counts in the subgranular zone of the dentate gyrus in
the four isoflurane-concentration groups (Control =
0%). When all animals with isoflurane exposure were
combined as one group (irrespective of concentrations
and days of recovery) and compared to the control ani-
mals as another group, the nonparametric independent-
samples tests, including the Kruskal-Wallis test and
median test, showed that the number of BrdU+ cells in
the subgranular zone of the dentate gyrus is significantly
different between the isoflurane-exposed animals and
the controls (p = 0.017, Kruskal-Wallis test; p = 0.029,
median test). The median and the 25th and 75th percen-
tiles of BrdU+ cell counts in the subgranular zone were
8, 2, and 12, respectively. Seven out of eight control
Figure 1 Immunohistochemical staining of apoptotic and anti-
apoptotic signals in the hippocampal Cornu Ammonis layer 1
(CA1) regions. A-C: Activated caspase-3 staining (green) revealed
no apoptosis in isoflurane-exposed animals (A), whereas positive
control from a mouse after 20-min of hypoxia exhibited activated
caspase-3+ cells (B). C is higher magnification of area outlined in B.
D-F: Bcl-xl immunostaining in the hippocampal CA1 regions (red)
revealed no anti-apoptotic response in isoflurane-exposed animals
(D), whereas positive control from a mouse after 20 min of hypoxia
exhibited Bcl-xl+ cells (E). F is a higher magnification of area
outlined in E. Cell nuclei are stained with DAPI (blue).
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animals had a BrdU+ cell count greater than the median,
whereas 22 out of 35 isoflurane-exposed animals had a
count less than or equal to the median. A closer exami-
nation of the data indicated that exposure to 0.6% and
2% of isoflurane seemed to reduce the total number of
BrdU+ cells in the subgranular zone of the dentate gyrus
6 and 14 d after the exposure.
Neurogenesis in the dentate gyrus was measured by
Dcx immunostaining. We found no differences in either
the Dcx+ cell counts (p = 0.055) or Dcx+ cell densities
(p = 0.096) in the subgranular zone of the dentate gyrus
between animals in the control group and those exposed
to isoflurane (Figure 3). Thus, 2-h isoflurane exposure in
the 0.6-2% range had a tendency in the later recovery
days to reduce cell proliferation, but did not affect neu-
rogenesis in young adult brains.
To investigate the effect of isoflurane exposure on glial
cells, we measured the density of glial cell processes and
reactive astrocytosis in the hippocampal molecular layer
and the granular layer and hilus of the dentate gyrus
using GFAP and VIM staining. Astrocytes are positive
for GFAP but usually become negative for VIM when
they mature. However, when the brain tissue is injured
or under stress, astrocytes can become reactive and re-
express VIM. Microglia and radial glia are also positive
for VIM. Using thresholding segmentation, we found
that over the observed period, exposure to isoflurane
caused a significant decrease in GFAP and VIM immu-
noreactivity in the three hippocampal formations studied
(Figure 4).
We first examined if the injection of BrdU interacted
with isoflurane exposure in terms of GFAP and VIM
expression. We compared the 24 animals that were
exposed to 1.3% isoflurane for 2 h. Half of these animals
received a BrdU injection for evaluating cell prolifera-
tion and the other half had no BrdU injection. One-way
ANOVA with respect to BrdU injection showed no
measureable effects on GFAP and VIM expression in
the three regions analyzed (p = 0.87). We then studied
the effects of anesthetic concentration and recovery
time after anesthetic exposure on GFAP and VIM
expression (Figure 5). Multivariate ANOVA showed that
GFAP expression in SLM and in the granular cell layer
and hilus of dentate gyrus were significantly affected by
anesthetic concentrations and the days of recovery (p =
0.000 for anesthetic concentrations and p = 0.027 for
days of recovery, with an observed power of 0.980 and
0.870, respectively, using the Pillai’s Trace test). VIM
expression in the three regions was significantly depen-
dent on anesthetic concentrations (p = 0.030, Pillai’s
trace and Wilks’ Lambda) but not on days of recovery
(p = 0.202 and 0.162, Pillai’s trace and Wilks’ Lambda).
For GFAP, post hoc pair-wise comparisons showed that
GFAP expressions were significantly different in hilus
between 2-h and 14-day recovery (p = 0.015) and
between 1-d and 14-d recovery (p = 0.002); in dentate
gyrus granular layer between 1-d and 6-d recovery (p =
0.004) and between 1-d and 14-d recovery (p = 0.007);
and in SLM between 1-d and 14-d recovery (p = 0.01).
Post-hoc pairwise comparisons among anesthetic con-
centrations showed that GFAP expressions were signifi-
cantly different between the control and 2%, 0.6% and
2%, and 1.3% and 2% in hilus and SLM, but no differ-
ence in GFAP expression was found between different
anesthetic concentrations in the granule layer of the
Figure 2 Counting of the number of BrdU+ cells in the
subgranular zone of dentate gyrus. All animals that received
BrdU injection were grouped by isoflurane (isof.) concentrations
(Control = 0%), irrespective of recovery time. Error bars show the
median and the 25th and 75th percentiles.
Figure 3 Quantification of doublecortin+ (Dcx+) cell densities
(in unit of Dcx+ cells/mm2) in the dentate gyrus subgranular
zone, showing no statistically significant difference among
groups.
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dentate gyrus. For VIM, simple contrast analysis showed
that 2% isoflurane exposure caused significant difference
in VIM expression compared to the control in SLM (p
= 0.031), granule layer (p = 0.020), and hilus (p = 0.002).
Discussion
In this study, we investigated the effects of the volatile
anesthetic isoflurane on possible mechanisms of anes-
thetic-induced neuroprotection and neurotoxicity in
adult mouse brains. The main conclusions of this
study are that isoflurane does not alter neurogenesis,
nor does it cause neuronal cell death, in various for-
mations of the hippocampus, which is known to be
selectively vulnerable to insults. Instead, the clinical
concentrations of isoflurane resulted in a decrease in
GFAP and VIM immunoreactivity after anesthetic
exposure, suggesting that glial cells and microglia may
be involved in the neurological changes seen with iso-
flurane anesthesia.
Our results are in agreement with the recent findings
of Stratmann et al [3], but differ from the conclusion
derived from studies with neonatal rodents [17,18].
Although the duration of isoflurane exposure is different
between the present and previous studies (e.g., 2 versus
6 h), this difference is nonessential to account for the
discrepancy seen in the apoptotic responses. In develop-
ing brains, pruning of neuronal processes occurs
through apoptosis to eliminate new neurons that fail to
make synaptic connections. This process is essential
during the synaptogenesis period. General anesthetics,
particularly those that potentiate the inhibitory action of
GABAA receptors and inhibit the excitatory action of
NMDA receptors, are known to interfere with synaptic
functions, including the establishment of new synapses.
Thus, it is an anticipated result of the natural and pro-
tective pruning process that prolonged exposure to iso-
flurane will lead to the appearance of increased
apoptosis in the neonatal brains undergoing
Figure 4 Immunohistochemical analysis of GFAP and VIM in representative regions of the dentate gyrus granule layer, hilus, and
hippocampal molecular layer. Notice the reduced immunoreactivities at the later time points in the isoflurane-exposed animals.
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synaptogenesis. The results in this study indicate that in
young adult mice after the synaptogenesis period, iso-
flurane does not cause neuronal apoptosis. Thus, extra-
polation of rodent studies to pediatric anesthesia should
be approached with caution. In rodents, synaptogenesis
starts to accelerate on postnatal day 7 (P7) and com-
pletes on P14 [9], whereas in humans, synaptogenesis
slowly increases during the first five years after birth,
accelerates to peak at age 10, and gradually plateaus
around age 16 [19]. Although a direct comparison of
time between humans and rodents is not possible,
simply by the proportion of the anesthetic exposure
time to the total synaptogenesis time, one can estimate
that a 6-h continuous exposure to isoflurane [17] during
the synaptogenesis period in rodents (i.e., 6 hours out of
14 days) would be equivalent time-wise to continuous
administration of isoflurane for 30-65 days out of 5-10
years of synaptogenesis in humans–a clinical scenario
that almost never happens. The duration of routine
anesthesia procedures in children, compared to the time
period of synaptogenesis in humans, is so insignificant
that the amount of anesthesia-induced apoptosis, if any,
Figure 5 Quantification of percent GFAP+ and percent VIM+ areas in the dentate gyrus granule layer, hilus, and hippocampal
molecular layer at different anesthetic concentrations over days of observation. Red, blue, green, and purple bars represent control, 0.6%,
1.3%, and 2% isoflurane exposure groups, respectively. Depicted are percentage of GFAP+ immunoreactivity in the granule layer (A), hilus (B), and
hippocampal molecular layer (C) and percentage of VIM+ immunoreactivity in the granule layer (D), hilus (E), and hippocampal molecluar layer
(F). Notice the marked reduction in GFAP and VIM at later time points especially at the higher concentration of isoflurane. *, p < 0.05; #, p <
0.01.
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is unlikely to have any long lasting impact on neuronal
structuring during brain development. Further research
is clearly needed to directly assess anesthetic effects on
the synaptogenesis and brain development in humans.
A recent study in C57/BL6 mice found that a 2-h
exposure to isoflurane induced caspase activation in a
narrow time window [20]. No caspase-3 activation was
detected 2 h and 24 h after isoflurane exposure, but
there was an increase after 6 h. We did not detect cas-
pase-3 activation in the current study, including at the
time point of 6 h after isoflurane exposure. However,
most of the animals in the current study were evaluated
for caspase on Days 1, 6, and 14 after the exposure.
Therefore, our conclusion is in general agreement with
the previous finding. We cannot rule out the possibility
that a narrow window of caspase-3 activation in CD1
mice was missed among the time points used in the cur-
rent study.
Our results, however, did show some delayed effects
from isoflurane exposure on glial cells, particularly
astrocytes. Since astrocytes are the supporting cells of
the central nervous system, it seems plausible that
they could play a significant role in mediating neuro-
nal survival versus neuronal death in response to anes-
thetics. Reactive astrocytosis is known to be protective
early in neuronal injury as the astrocytes regulate the
external chemical environment of the neurons. When
the hyperplasia and hypertrophy of astrocytes are pro-
longed, however, injury occurs as a result of glial scar-
ring, which creates a barrier to axonal regeneration
and synaptogenesis [21]. In rats pre-treated with rat
umbilical cord matrix (RUCM) cells, there was less
reactive astrocytosis as measured by VIM reactivity
and concurrently less neuronal loss in the hippocam-
pus after 8-minute global cerebral ischemia, suggesting
that the stem cells were able to mitigate the neuronal
injury secondary to the post-ischemic reactive astrocy-
tosis response [22,23]. Likewise, knocking down VIM
expression using antisense complementary DNA for
VIM [24] or preventing hypertrophy of astrocytic pro-
cesses in GFAP-/-VIM-/-double knockout mice [25]
can reduce glial scarring and improve neuronal regen-
eration and recovery after traumatic brain injuries.
Therefore, the significant decrease in GFAP+ and VIM
+ astroglia after anesthetic exposure as observed in
this study may offer an alternative explanation of neu-
roprotection seen in other experimental studies of
brain injuries involving the use of isoflurane
anesthesia.
Several studies have focused on the neuronal
responses to isoflurane anesthesia. In a study of trau-
matic brain injury (TBI) [26], CA3 neuronal survival in
rats with TBI was better in those pretreated with isoflur-
ane. The neuroprotective actions of isoflurane have been
thought to be due to vasodilation and attenuation of
excitotoxicity [27]. Neuroprotection by volatile anes-
thetics has also been observed with sevoflurane-induced
neurogenesis in the dentate gyrus after cerebral ische-
mia. The current thought is that sevoflurane stimulates
the hippocampal GABA interneurons, which in turn
activate the progenitor cells in the dentate gyrus subgra-
nular zone [28,29]. Although we did not find changes in
neurogenesis after isoflurane exposure without addi-
tional insults, it is plausible that the degree of neurogen-
esis in the dentate gyrus after ischemia could be
impacted by the amount of reactive astrocytosis; less
astrocytosis after anesthetic exposure may allow for
more neurogenesis as more axonal regeneration and
synaptogenesis would be enabled.
In conclusion, exposure to isoflurane for two hours
did not cause neural apoptosis in the adult mouse brain.
Without additional insults, isoflurane exposure alone
did not lead to enhanced neurogenesis in the dentate
gyrus, one of the two neurogenesis regions in the adult
brain. Two weeks after isoflurane exposure, the astrocy-
tic processes, as measured by the GFAP+ and VIM+
areas, which are proportional to the density of GFAP+
and VIM+ immunoreactivity, were significantly reduced.
Future studies are needed to determine if anesthetic-
induced hypotrophy of glial processes will be beneficial
in preventing glial scarring in the presence of other
insults such as ischemia and traumatic injuries.
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